Abstract
IntroductionThere is evidence that biosimilar infliximab (BSI) has comparable efficacy and safety to originator infliximab (OI) and is significantly cheaper.ECCO guidelines suggest therapeutic drug monitoring (TDM) can help determine whether...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
